Clinical Trials Browser

NCT07459634 2026-05-27

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

Phase 2 Not yet recruiting

50 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT05800587 2026-05-22

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Phase 2 Recruiting

280 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT06503146 2026-05-19

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Phase 2 Recruiting

320 enrolled

CNSEndocrineGastrointestinalGenitourinaryGynecologicOther solid neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Ovarian Neoplasms, Paraganglioma, Pheochromocytoma, Sarcoma, Stomach Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma

Clinical Trials

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

SEZanne

PrE0510

Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

SKB500 Combinations in Patients With Small Cell Lung Cancer

PF-07104091 as a Single Agent and in Combination Therapy

Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment

MERLIN

A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC

MOZART

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

SMARCA4/2 Inhibitor for POU2F3-Positive SCLC

TAZMAN

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

DURVALUNG

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

T-BRAIN

Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

Aurora004

Aurora 005

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

ACHILES

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

MGC018-SCLC

STAR-01

Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer

Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

Study of Trilaciclib and Lurbinectidin

Phase 2 Study of Fingolimod in Lung Cancers

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Durvalumab as Consolidation for Patients LS-SCLC

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression

ALISCA-Lung2

Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

DeLLphi-309